

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (original) A method of treating a papillomavirus related epithelial disorder comprising administering to a subject in need thereof a therapeutically effective amount of one or more iron/zinc chelators and one or more cruciferous indoles.
2. (original) The method of claim 1, where the one or more chelators and one or more indoles are administered simultaneously.
3. (original) The method of claim 1, wherein the one or more chelators and one or more indoles are administered within a short time of one another.
4. (original) The method of claim 1, wherein the one or more indoles are administered orally.
5. (original) The method of claim 1, wherein the one or more iron/zinc chelators and one or more cruciferous indoles are administered topically.
6. (original) The method of claim 1, wherein the amount of the one or more indoles is lower than that which is therapeutically effective when the one or more indoles are administered in the absence of the one or more chelators.
7. (original) The method of claim 1, wherein the amount of the one or more chelators is lower than that which is therapeutically effective when the one or more chelators are administered in the absence of the one or more indoles.
8. (original) The method of claim 6, wherein the amount of the one or more chelators is lower than that which is therapeutically effective when the one or more chelators are administered in the absence of the one or more indoles.

9. (original) The method of claim 1 wherein the one or more chelators and the one or more indoles act synergistically.
10. (original) The method of claim 1, further comprising the administration of a therapeutically effective amount of one or more compounds selected from the group consisting of gallium, a gallium salt, a zinc-binding histone deacetylase inhibitor and an EGFR antagonist.
11. (original) The method of claim 1, further comprising the administration of a therapeutically effective amount of gallium or a gallium salt.
12. (original) The method of claim 11, wherein said gallium is gallium-67.
13. (original) The method of claim 11, wherein the one or more chelators have an affinity for gallium and an affinity for iron/zinc, and wherein the affinity for gallium is less than the affinity for iron/zinc.
14. (original) The method of claim 1 where the one or more indoles are selected from the group consisting of Diindolylmethane (DIM), hydroxy-DIMs, methoxy-DIMs, imidazolelyl-3,3'-diindolylmethane, nitro substituted imidazolelyl-3,3'-diindolylmethanes, 2-hydroxy estrogens, and 2-methoxy estrogens.
15. (original) The method of claim 1 wherein the one or more chelators are selected from the group consisting of Desferrioxamine (DFO), 3,5,7,-trihydroxy-2-[3-(4-hydroxy-3-methoxyphenyl)-2-hydroxymethyl-1,4-benzodioxan-6-yl]-chronan-4-one (Silybin), ethylenediametetraacetic acid [EDTA], ethylenetriaminepentaacetic acid [DTPA], 1,2-Dimethyl-3-hydroxypyrid-4-one (deferiprone, Ferriprox [L1]), Desferri-Exochelin [DFE 772SM], N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid (HBED), picolinic acid, 3-hydroxypicolinic acid, Fuscaric acid, 2,2'-bipyridyl (dipyridine [bipyridyl]), 2,2'-bipyridyl-6-carbothioamide (BPYTA), 1,10-Phenanthroline and sodium butyrate.
16. (original) The method of claim 1 wherein the papillomavirus related epithelial disorder is selected from the group consisting of oral-genital human papilloma virus

infection, oropharyngeal human papilloma virus-related papillomas and dysplasia, peri-anal human papilloma virus-related papilloma and dysplasia, vaginal human papilloma virus-related papilloma and dysplasia, uterine cervical human papilloma virus-related papilloma and dysplasia, skin-related human papilloma virus infection (warts or verrucae), human papilloma virus-related cancer, basal cell carcinoma of the skin, carcinoma of the uterine cervix, carcinoma of the uterine endometrium, and carcinoma of the colon.

17. (original) The method of claim 1 wherein the papillomavirus related epithelial disorder is an human papilloma virus-related ophthalmic infection.

18. (original) The method of claim 1 or 10 further comprising administering a radiation therapy regimen sufficient to treat a papillomavirus-related disease.

19. (original) The method of claim 18 wherein said radiation therapy comprises topical irradiation with ultraviolet radiation or x-rays.

20. (original) A pharmaceutical composition comprising a therapeutically effective amount of the combination of one or more iron/zinc chelators and one or more cruciferous indoles.

21. (original) The composition of claim 20, wherein the composition is formulated for oral administration.

22. (original) The composition of claim 20, wherein the amount of the one or more indoles is lower than that which is therapeutically effective when the one or more indoles are administered in the absence of the one or more chelators.

23. (original) The composition of claim 20, wherein the amount of the one or more chelators is lower than that which is therapeutically effective when the one or more chelators are administered in the absence of the one or more indoles.

24. (original) The composition of claim 22, wherein the amount of the one or more chelators is lower than that which is therapeutically effective when the one or more chelators are administered in the absence of one or more indoles.
25. (original) The composition of claim 20 wherein the combination is synergistic.
26. (original) The composition of claim 20, further comprising a therapeutically effective amount of one or more compounds selected from the group consisting of gallium a gallium salt, a zinc-binding histone deacetylase inhibitor and an EGFR antagonist
27. (original) The composition of claim 20, further comprising a therapeutically effective amount of gallium or a gallium salt.
28. (original) The composition of claim 27, wherein said gallium is gallium-67.
29. (original) The composition of claim 27, wherein the one or more chelators have an affinity for gallium and an affinity for iron/zinc, and wherein the affinity for gallium is less than the affinity for iron/zinc.
30. (original) The composition of claim 20, wherein the one or more indoles are selected from the group consisting of Diindolylmethane (DIM), hydroxy-DIMs, methoxy-DIMs, imidazolelyl-3,3'-diindolylmethane, nitro substituted imidazolelyl-3,3'-diindolylmethanes, 2-hydroxy estrogens, and 2-methoxy estrogens.
31. (original) The composition of claim 20 wherein the one or more chelators are selected from the group consisting of Desferrioxamine (DFO), 3,5,7,-trihydroxy-2-[3-(4-hydroxy-3-methoxyphenyl)-2-hydroxymethyl-1,4-benzodioxan-6-yl]-chronan-4-one (Silybin), ethylenediametetraacetic acid [EDTA], ethylenetriaminepentaacetic acid [DTPA], 1,2-Dimethyl-3-hydroxypyrid-4-one (deferiprone, Ferriprox [L1]), Desferri-Exochelin [DFE 772SM], N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid (HBED), picolinic acid, 3-hydroxypicolinic acid, Fuscic acid, 2,2'-bipyridyl (dipyridine [bipyridyl]), 2,2'-bipyridyl-6-carbothioamide (BPYTA), 1,10-Phenanthroline and sodium butyrate.

32. (new) The composition of claim 20, wherein the composition is formulated for aerosol administration.
33. (new) The composition of claim 30, wherein the indole is Diindolylmethane (DIM).
34. (new) The composition of claim 31, wherein the chelator is sodium butyrate.